Truist Securities on Insmed (INSM): brensocatib in HS failure unsuprising, 'stock doesn't reflect any meaningful value for HS'
Tweet Send to a Friend
Truist Securities analyst Danielle Brill reiterated a Buy rating and $205.00 price target on Insmed (NASDAQ: INSM)The analyst commented, "Insmed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
